propranolol has been researched along with Iron Overload in 4 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Iron Overload: An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
| Excerpt | Relevance | Reference |
|---|---|---|
| "d-Propranolol (d-Pro: 2-8 mg·(kg body mass)(-1)·day(-1)) protected against cardiac dysfunction and oxidative stress during 3-5 weeks of iron overload (2 mg Fe-dextran·(g body mass)(-1)·week(-1)) in Sprague-Dawley rats." | 7.78 | d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats. ( Chmielinska, JJ; Iantorno, M; Kramer, JH; Mak, IT; Spurney, CF; Tziros, C; Weglicki, WB, 2012) |
| "The protective effects of carvedilol, via its antioxidant effect, may have therapeutic potential in patients with iron overload." | 3.80 | Carvedilol protects against iron-induced microparticle generation and apoptosis of endothelial cells. ( Cao, JM; Chan, GC; Chan, S; Chen, MP; Cheung, YF, 2014) |
| "Iron overload was generated by intraperitoneal injections of iron dextran (1g/kg) administered once a week for 8 weeks in male C57bl/6 mice, while propranolol was administered in drinking water at the dose of 40 mg/kg/day." | 3.79 | The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice. ( Catalano, L; Corritore, E; Maccari, S; Marano, G; Massimi, A; Musumeci, M; Sestili, P, 2013) |
| "d-Propranolol (d-Pro: 2-8 mg·(kg body mass)(-1)·day(-1)) protected against cardiac dysfunction and oxidative stress during 3-5 weeks of iron overload (2 mg Fe-dextran·(g body mass)(-1)·week(-1)) in Sprague-Dawley rats." | 3.78 | d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats. ( Chmielinska, JJ; Iantorno, M; Kramer, JH; Mak, IT; Spurney, CF; Tziros, C; Weglicki, WB, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, S | 1 |
| Chen, MP | 1 |
| Cao, JM | 1 |
| Chan, GC | 1 |
| Cheung, YF | 1 |
| Musumeci, M | 1 |
| Maccari, S | 1 |
| Sestili, P | 1 |
| Massimi, A | 1 |
| Corritore, E | 1 |
| Marano, G | 1 |
| Catalano, L | 1 |
| Kramer, JH | 1 |
| Spurney, CF | 1 |
| Iantorno, M | 1 |
| Tziros, C | 1 |
| Chmielinska, JJ | 2 |
| Mak, IT | 2 |
| Weglicki, WB | 2 |
| Landgraf, KM | 1 |
4 other studies available for propranolol and Iron Overload
| Article | Year |
|---|---|
Carvedilol protects against iron-induced microparticle generation and apoptosis of endothelial cells.
Topics: Adrenergic beta-Antagonists; Annexin A5; Apoptosis; Carbazoles; Carvedilol; Caspase 3; Cell-Derived | 2014 |
The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channels, L-Type; Disease Models, Animal; Disease Resi | 2013 |
d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats.
Topics: Acetylglucosaminidase; Adrenergic beta-Antagonists; Animals; Cardiac Output; Disease Progression; Do | 2012 |
Angiotensin II promotes iron accumulation and depresses PGI₂ and NO synthesis in endothelial cells: effects of losartan and propranolol analogs.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta | 2012 |